CHCory M. Hogaboam

Cory M. Hogaboam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cory M. Hogaboam has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Steven L. Kunkel

    Departments of Pathology, University of Michigan Medical School , Ann Arbor, MI 48109

    9 shared publications
  • Nicholas W. Lukacs

    Departments of Pathology, University of Michigan Medical School , Ann Arbor, MI 48109

    8 shared publications
  • Matthew L. Steinhauser

    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan

    5 shared publications
  • Robert M. Strieter

    Division of Pulmonary and Critical Care University of Michigan Medical School Ann Arbor Michigan 48109‐0602 USA

    5 shared publications
  • Kate Blease

    Department of Pathology, Division of Pulmonary and Critical Care, University of Michigan Medical School, Ann Arbor, MI 48109, USA

    3 shared publications
  • Akihiro Matsukawa

    2 shared publications

Latest Publications

  • Open Access

    Antifungal and Airway Remodeling Roles for Murine Monocyte Chemoattractant Protein-1/CCL2 During Pulmonary Exposure to Asperigillus fumigatus Conidia

    by Kate Blease, Borna Mehrad, Nicholas W. Lukacs, Steven L. Kunkel, Theodore J. Standiford, Cory M. Hogaboam

    Asperigillus fumigatus spores or conidia are quickly eliminated from the airways of nonsensitized individuals but persist in individuals with allergic pulmonary responsiveness to fungus. A. fumigatus-induced allergic airway disease is characterized by persistent airway hyperreactivity, inflammation, and fibrosis. The present study explored the role of CCR2 ligands in the murine airway response to A. fumigatus conidia. Nonsensitized and A. fumigatus-sensitized CBA/J mice received an intratracheal challenge of A. fumigatus conidia, and pulmonary changes were analyzed at various times after conidia. Whole lung levels of monocyte chemoattractant protein-1 (MCP-1/CCL2), but neither MCP-3/CCL7 nor MCP-5/CCL12, were significantly elevated at days 3 and 7 after conidia in nonsensitized mice. MCP-1/CCL2 was significantly increased in lung samples from A. fumigatus-sensitized mice at days 14 and 30 after a conidia challenge. Administration of anti-MCP-1/CCL2 antiserum to nonsensitized mice for14 days after the conidia challenge attenuated the clearance of conidia and significantly increased airway hyperreactivity, eosinophilia, and peribronchial fibrosis compared with nonsensitized mice that received conidia and normal serum. Adenovirus-directed overexpression of MCP-1/CCL2 in A. fumigatus-sensitized mice markedly reduced the number of conidia, airway inflammation, and airway hyperresponsiveness at day 7 after the conidia challenge in these mice. Immunoneutralization of MCP-1/CCL2 levels in A. fumigatus-sensitized mice during days14–30 after the conidia challenge did not affect the conidia burden but significantly reduced airway hyperreactivity, lung IL-4 levels, and lymphocyte recruitment into the airways compared with the control group. These data suggest that MCP-1/CCL2 participates in the pulmonary antifungal and allergic responses to A. fumigatus conidia.


  • Acute inhibition of nitric oxide exacerbates airway hyperresponsiveness, eosinophilia and C-C chemokine generation in a murine model of fungal asthma

    by K. Blease, S.L. Kunkel, C.M. Hogaboam

    Objective and Design: This study examined he role of nitric oxide in changes in airway physiology and inflammation in a murine model of fungal allergy induced by Aspergillus fumigatus (A. fumigatus) by treatment of A. fumigatus-sensitized mice with NG-nitro-L-arginine methyl ester (L-NAME) or D-NAME (8 mg/kg; i.p.).¶Materials and Methods: Female CBA/J mice received A. fumigatus antigen dissolved in incomplete Freund's adjuvant (10 mg/100 ml i.p. and s.c.) followed 2 weeks later by A. fumigatus antigens (20 mg; i.n.) and a subsequent i.t. challenge 4 days later. Airway physiology and inflammation were examined (24 to 72 h) following i.t. challenge.¶Results: L-NAME-treated mice had lower lung nitrite levels 24 h after A. fumigatus challenge, but higher airway hyperresponsiveness and inflammation compared to D-NAME controls. Airway inflammation in the L-NAME treatment group (72 h) was characterized by a greater bronchoalveolar lavage (BAL), peribronchial eosinophilia and augmented levels of CC chemokines compared to controls.¶Conclusions: These findings suggest that nitric oxide is an important modulator of airway hyperresponsiveness, inflammation and C-C chemokine generation during allergic airway responses to A. fumigatus.


  • On the mechanisms underlying the protective role of M-CSF dependent macrophages in experimental colitis in mice

    by Francesca Galeazzi, Cory M. Hogaboam, Bruce A. Vallance, Stephen M. Collins

  • Exaggerated Hepatic Injury Due to Acetaminophen Challenge in Mice Lacking C-C Chemokine Receptor 2

    by Cory M. Hogaboam, Cynthia L. Bone-Larson, Matthew L. Steinhauser, Akihiro Matsukawa, Jennifa Gosling, Landin Boring, Israel F. Charo, Kenneth J. Simpson, Nicholas W. Lukacs, Steven L. Kunkel


  • Therapeutic Use of Chemokines

    by Cory M. Hogaboam, Cynthia Bone-Larson, Akihiro Matsukawa, Matthew L. Steinhauser, Kate Blease, Nicholas W. Lukacs, Steven L. Kunkel

    Chemokines are involved in a number of pathological processes, and therefore represent important targets. However, it has also become apparent that chemokines have exciting therapeutic applications in inflammatory, infectious and cancer-related diseases. The following review will highlight the application of novel therapies including viral-encoded, recombinant, and genetically engineered chemokines to a number of diseases or disorders. Advances in the application of novel chemokine delivery procedures both at the research bench and the clinical bedside will also be discussed. Overall, the utilization of chemokines to prevent and treat disease has tremendous potential.


  • Chronic Airway Hyperreactivity, Goblet Cell Hyperplasia, and Peribronchial Fibrosis during Allergic Airway Disease Induced by Aspergillus fumigatus

    by Cory M. Hogaboam, Kate Blease, Borna Mehrad, Matthew L. Steinhauser, Theodore J. Standiford, Steven L. Kunkel, Nicholas W. Lukacs


  • Novel CXCR2‐dependent liver regenerative qualities of ELR‐containing CXC chemokines

    by Cory M. Hogaboam, Cynthia L. Bone‐Larson, Matthew L. Steinhauser, Nicholas W. Lukacs, Lisa M. Colletti, Ken J. Simpson, Robert M. Strieter, Steven L. Kunkel

    Severe acute liver injury due to accidental or intentional acetaminophen overdose presents a major clinical dilemma often requiring liver transplantation. In the present study, liver regeneration after profound liver injury in mice challenged with acetaminophen was facilitated by the exogenous addition of ELR‐containing CXC chemokines such as macrophage inflammatory protein‐2 (MIP‐2), epithelial neutrophil‐activating protein‐78 (ENA‐78), or interleukin 8. Intravenous administration of ELR‐CXC chemokines or N‐acetyl‐cysteine (NAC) immediately after acetaminophen challenge in mice significantly reduced histological and biochemical markers of hepatic injury. However, when the intervention was delayed until 10 h after acetaminophen challenge, only ELR‐CXC chemokines significantly reduced liver injury and mouse mortality. The delayed addition of ELR‐CXC chemokines to cultured hepatocytes maintained the proliferation of these cells in a CXCR2‐dependent fashion after acetaminophen challenge whereas delayed NAC treatment did not. These observations demonstrate that ELR‐CXC chemokines represent novel hepatic regenerative factors that exhibit prolonged therapeutic effects after acetaminophen‐induced hepatotoxicity.—Hogaboam, C. M., Bone‐Larson, C. L., Steinhauser, M. L., Lukacs, N. W., Colletti, L. M., Simpson, K. J., Strieter, R. M., Kunkel, S. L. Novel CXCR2‐dependent liver regenerative qualities of ELR‐containing CXC chemokines. FASEB J . 13, 1565–1574 (1999)


  • Open Access

    Differential Monocyte Chemoattractant Protein-1 and Chemokine Receptor 2 Expression by Murine Lung Fibroblasts Derived from Th1- and Th2-Type Pulmonary Granuloma Models

    by Cory M. Hogaboam, Cynthia L. Bone-Larson, Scott Lipinski, Nicholas W. Lukacs, Stephen W. Chensue, Robert M. Strieter, Steven L. Kunkel

    Recent studies suggest that monocyte chemoattractant protein-1 (MCP-1) is involved in fibrosis through the regulation of profibrotic cytokine generation and matrix deposition. Changes in MCP-1, C-C chemokine receptor 2 (CCR2), procollagen I and III, and TGF β were examined in fibroblasts cultured from normal lung and from nonfibrotic (i.e., Th1-type) and fibrotic (i.e., Th2-type) pulmonary granulomas. Th2-type fibroblasts generated 2-fold more MCP-1 than similar numbers of Th1-type or normal fibroblasts after 24 h in culture. Unlike normal and Th1-type fibroblasts, Th2-type fibroblasts displayed CCR2 mRNA at 24 h after IL-4 treatment. By flow cytometry, CCR2 was present on 40% of untreated Th2-type fibroblasts, whereas CCR2 was present on <20% of normal and Th1-type fibroblasts after similar treatment. IL-4 increased the number of normal fibroblasts with cell-surface CCR2 but IFN-γ-treatment of normal and Th2-type fibroblasts significantly decreased the numbers of CCR2-positive cells in both populations. Western blot analysis showed that total CCR2 protein expression was markedly increased in untreated Th2-type fibroblasts compared with normal and Th1-type fibroblasts. IL-4 treatment enhanced CCR2 protein in Th1- and Th2-type fibroblasts whereas IFN-γ treatment augmented CCR2 protein in normal and Th1-type fibroblasts. All three fibroblast populations exhibited MCP-1-dependent TGF-β synthesis, but only normal and Th2-type fibroblasts showed a MCP-1 requirement for procollagen mRNA expression. Taken together, these findings suggest that lung fibroblasts are altered in their expression of MCP-1, TGF-β, CCR2, and procollagen following their participation in pulmonary inflammatory processes, and these changes may be important during fibrosis.


  • Open Access

    Immunomodulatory Role of C10 Chemokine in a Murine Model of Allergic Bronchopulmonary Aspergillosis

    by Cory M. Hogaboam, Chad S. Gallinat, Dennis D. Taub, Robert M. Strieter, Steven L. Kunkel, Nicholas W. Lukacs

    The immunomodulatory role of the chemokine C10 was explored in allergic airway responses during experimental allergic bronchopulmonary aspergillosis (ABPA). The intratracheal delivery of Asperigillus fumigatus Ag into A. fumigatus-sensitized mice resulted in significantly increased levels of C10 within the bronchoalveolar lavage, and these levels peaked at 48 h after A. fumigatus challenge. In addition, C10 levels in BAL samples were greater than 5-fold higher than levels of other chemokines such as monocyte-chemoattractant protein-1, eotaxin, and macrophage-inflammatory protein-1α. From in vitro studies, it was evident that major pulmonary sources of C10 may have included alveolar macrophages, lung fibroblasts, and vascular smooth muscle cells. Experimental ABPA was associated with severe peribronchial eosinophilia, bronchial hyperresponsiveness, and augmented IL-13 and IgE levels. The immunoneutralization of C10 with polyclonal anti-C10 antiserum 2 h before the intratracheal A. fumigatus challenge significantly reduced the airway inflammation and hyperresponsiveness in this model of ABPA, but had no effect on IL-10 nor IgE levels. Taken together, these data suggest that C10 has a unique role in the progression of experimental ABPA.


  • Collagen Deposition in a Non-Fibrotic Lung Granuloma Model after Nitric Oxide Inhibition

    by Cory M. Hogaboam, Chad S. Gallinat, Cynthia Bone-Larson, Stephen W. Chensue, Nicholas W. Lukacs, Robert M. Strieter, Steven L. Kunkel